In Risky Move, Alpharma Launches Generic Neurontin

Law360, New York (October 10, 2004, 12:00 AM EDT) -- In a risky move, Alpharma Inc. on Friday launched a generic version of Pfizer’s blockbuster epilepsy drug Neurontin without waiting for a court ruling on Pfizer's motion for a preliminary injunction.

Alpharma said the drug had already been shipped to wholesalers in 100 milligram, 300 mg and 400 mg doses, a step likely to sharply undercut Pfizer’s share of the $2.4 billion market for the drug.

Pfizer immediately struck back by launching its own generic version of the drug through its Greenstone Ltd. subsidiary.

“While Judge...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.